WednesdayJan 28, 2026 10:00 am

Novel Therapy Helps Tumor Cells Welcome Cancer Treatment

For years, one of the biggest frustrations in cancer care has been watching immunotherapy succeed spectacularly in some diseases while stalling almost completely in others. Solid tumors, especially those that spread aggressively, have remained stubbornly resistant, not because the immune system cannot kill them, but because it often cannot get close enough to try. New research from a U.S. academic team suggests that this long-standing barrier may be more fragile than once believed.  Rather than attacking cancer cells head-on, the scientists focused on dismantling the internal defenses that shield tumors from immune attack, effectively forcing them to open themselves to treatment. The work, published in the journal Cancer Cell in January, examined…

Continue Reading

TuesdayJan 27, 2026 10:30 am

GridAI Technologies Corp. (NASDAQ: GRDX) Names Marshall Chapin as the CEO for the Company’s AI and Energy Infrastructure Subsidiary, GridAI, Inc.

GridAI Technologies Corp., recently named Marshall Chapin as the CEO of the company’s wholly owned subsidiary, GridAI, Inc., which operates at the fast-growing intersection of AI and energy infrastructure. Grid AI, Inc. is an AI-driven software platform that allows utilities, energy retailers, and other large power users to manage energy resources far more effectively. Chapin brings decades of leadership experience across the energy sector to the table, with key roles at several companies and a proven track record when it comes to growth. GridAI Technologies Corp. (NASDAQ: GRDX), is an expanding company, advancing opportunities at the intersection of artificial intelligence…

Continue Reading

MondayJan 26, 2026 10:00 am

How Bitcoin is Already Being Impacted by Quantum Computing

Quantum computing is already affecting the cryptocurrency industry in several notable ways, and Bitcoin is increasingly at the center of that shift as investors reassess long-term technological risk. While fully capable quantum machines remain years away, their anticipated arrival is beginning to influence market behavior today, not through broken encryption, but through changing confidence.  One signal has been Bitcoin’s recent lag behind gold, a divergence that has caught the attention of institutional investors. Some strategists now argue that emerging quantum capabilities introduce a new category of risk that traditional valuation models struggle to price in. That uncertainty is starting to weigh on Bitcoin’s appeal as a long-term hedge and portfolio decisions are already reflecting this…

Continue Reading

FridayJan 23, 2026 9:00 am

ParaZero Technologies Ltd. (NASDAQ: PRZO) Expands Counter-UAS Capabilities and Strengthens Its Position in Modern Defense Systems

ParaZero recently advanced the deployment of its multi-layered Counter-UAS solutions for military and homeland security applications The company operates at the nexus of precision interception, autonomous aerospace systems, and defense innovation These updates underscore ParaZero’s mission to deliver scalable, low-collateral damage counter-drone defense systems for complex and urban environments ParaZero Technologies (NASDAQ: PRZO) is taking a leading role in the evolution of the counter-drone defense industry, as security agencies and military forces globally explore reliable alternatives to tackling the increased threats from unmanned aerial systems. With core specialization in multi-layered Counter-Unmanned Aircraft System (“Counter-UAS”) technologies, the company is positioning its products…

Continue Reading

ThursdayJan 22, 2026 9:45 am

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Advances a Novel Approach to Enhancing Cancer Therapy

LIXTE is developing a first-in-class therapy designed to enhance the effectiveness of existing cancer treatments Its lead compound, LB-100, targets PP2A and is advancing through multiple clinical trials with a favorable safety profile The company is building a differentiated oncology pipeline supported by experienced leadership and scientific expertise LIXTE Biotechnology (NASDAQ: LIXT) is a clinical-stage pharmaceutical company leading efforts in addressing some of the pressing challenges in cancer treatment. Instead of developing standalone cancer drugs, the company is adopting a different strategy aimed at enhancing the overall effectiveness of existing immunotherapy and chemotherapy regimens through a novel biological target. LIXTE’s…

Continue Reading

TuesdayJan 20, 2026 10:00 am

Study Discovers Molecule of Gut Bacteria That Boosts Immunotherapy Response

Scientists have identified a compound produced by gut bacteria that sharply improves how tumors respond to immunotherapy, offering a potential breakthrough for patients who currently see little benefit from these treatments. The discovery centers on a small molecule called Bac429, which enhanced lung cancer treatment outcomes in mice and is now being developed into a drug suitable for human trials.  The research was led by a team at the UF Health Cancer Institute and focuses on immune checkpoint inhibitors, a class of cancer drugs designed to help the immune system recognize and attack tumors. While these therapies have changed cancer care, their effectiveness remains limited. Rachel Newsome, study author…

Continue Reading

WednesdayJan 14, 2026 10:00 am

Cornell Researchers Develop Particles That Can Supercharge Immunotherapy

Cornell researchers have developed particles that can supercharge immunotherapy, offering a breakthrough approach to treating resistant cancers. The nanoparticles work in an unexpected dual capacity: they fundamentally alter hostile tumor conditions while amplifying the potency of existing immunotherapy drugs.  Survival outcomes in mouse experiments show the efficacy of the newly developed particles. Animals with aggressive melanoma receiving the particles combined with immunotherapy drugs targeting checkpoint proteins and immune signaling molecules lived significantly longer than those getting immunotherapy drugs alone. The particles reshaped conditions inside tumors, enabling the immunotherapy drugs to mount a far more effective assault on cancer cells.  The particles, designated Cornell prime dots…

Continue Reading

WednesdayJan 14, 2026 9:45 am

Rail Vision Ltd. (NASDAQ: RVSN) Is ‘One to Watch’

Rail Vision operates in large and growing markets for railway safety, collision avoidance, and autonomous train technologies supported by favorable long-term industry trends. The company’s purpose-built rail-focused technology addresses critical safety and operational challenges, positioning it for steady growth as rail operators continue to modernize globally. A growing global footprint, including deployments, pilots, and commercial agreements across multiple regions, demonstrates early commercial traction. Ongoing investment in intellectual property, including recently granted international patents, supports defensible technology positioning. A strengthened balance sheet and continued R&D investment enhance the company’s ability to support commercialization and product development initiatives. Rail Vision (NASDAQ: RVSN) is…

Continue Reading

WednesdayJan 14, 2026 9:00 am

ParaZero Technologies Ltd. (NASDAQ: PRZO) Announces First Successful Demonstration of the Company’s DefendAir Platform in Europe

ParaZero has successfully demonstrated the company’s DefendAir platform for the first time on European soil, following a distribution agreement that was recently signed with a leading Western European distributor Around 40 senior military officers representing several NATO member states from Western Europe attended the event where ParaZero demonstrated the full capabilities of DefendAir The live exercise showcased the platforms rapid deployment, precision targeting, interception success rate, and ability to operate well in complex environments ParaZero Technologies (NASDAQ: PRZO), an aerospace defense company, recently completed the company’s first live DefendAir demonstration on European soil. The successful demonstration followed a recently signed…

Continue Reading

MondayJan 12, 2026 10:00 am

Health IT Firms Call for Clearer, More Consistent AI Rules

Health IT firms in the U.S. are calling for clearer, more consistent AI rules as conflicting state regulations create mounting challenges for companies operating across multiple jurisdictions. Industry leaders say the fragmented approach to AI regulation threatens to slow innovation while producing unequal care standards for patients depending on their location.  President Donald Trump's administration addressed these concerns with a December 11 executive order titled Ensuring A National Policy Framework For Artificial Intelligence. The directive seeks to establish unified nationwide standards rather than permitting individual states to continue developing their own methods for regulating the rapidly evolving technology.  The order directs Attorney General Pam Bondi to establish an AI Litigation Task Force to address state laws deemed to be at odds with national policy. Commerce Secretary Howard Lutnick must review existing state AI legislation and…

Continue Reading

Contact us: (512) 354-7000